Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead, maker of Sovaldi.
from WSJ.com: US Business http://ift.tt/1zTKhFa
via IFTTT
from WSJ.com: US Business http://ift.tt/1zTKhFa
via IFTTT
No comments:
Post a Comment